Overview

Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Assessment of daily maintenance dose of Sifrol®, L-dopa sparing effect, effect on tremor, depression, anhedonia and tolerability
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Pramipexole